聚乙二醇化重组人粒细胞刺激因子在日间化疗中心患者中的应用分析

Application analysis of pegylated recombinant human granulocyte colony-stimulating factor for patients in day-time chemotherapy center

目的分析日间化疗中心患者使用聚乙二醇化重组人粒细胞刺激因子(PEG-rhG-CSF)的现状,为该药的管理提供参考数据。方法收集日间化疗中心在2019年5-7月使用PEG-rhG-CSF患者的病历资料,结合国内外指南及专家共识进行用药分析。结果日间化疗中心共254人340例次使用PEG-rhG-CSF,其中预防性使用305例次(89.71%),治疗性使用35例次(10.29%),均通过皮下注射给药,用药剂量分别为6 mg(84.41%)和3 mg(15.59%),剂量范围分别为69.36~166.2μg·kg^(-1)和34.09~83.33μg·kg^(-1)。预防性用药中,距上一程放化疗间隔符合指南标准的仅占27.87%。PEG-rhG-CSF距下一程放化疗<12 d及2次PEG-rhGCSF间隔<7 d分别占6.18%和1.29%。不良反应有白细胞增多、发热、疲乏和失眠。结论PEG-rhG-CSF在日间化疗中心以预防性使用为主,并存在一定的不合理现象,应重点关注距上一程放化疗间隔的问题。

AIM To analyze the current situation of pegylated recombinant human granulocyte colonystimulating factor(PEG-rhG-CSF)for patients in the day-time chemotherapy center and provide reference data for the management of this drug.METHODS The medical records of patients,who used PEG-rhG-CSF in the day-time chemotherapy center from May to July 2019,were collected and analyzed based on domestic and foreign guidelines and expert consensus.RESULTS PEG-rhG-CSF was administrated subcutaneously in 254 patients for 340 times in the daytime chemotherapy center,among them 305 times(89.71%)for prophylactic use and 35 times(10.29%)for therapeutic use with the dosage of 6 mg(84.41%)and 3 mg(15.59%),and the dosage range was 69.36-166.2μg·kg^(-1) and 34.09-83.33μg·kg^(-1) respectively.Only 27.87%of the patients met the guidelines for the intervals from the previous course of chemoradiotherapy.The time intervals<12 d and<7 d were 6.18%and 1.29%respectively.Adverse reactions included leukocytosis,fever,fatigue,and insomnia.CONCLUSION PEG-rhG-CSF is mainly used for prophylaxis in the day-time chemotherapy center,and there is some unreasonable phenomena in use.Attention should be paid to the interval from the previous course of chemoradiotherapy.